EA200900586A1 - Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов - Google Patents

Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов

Info

Publication number
EA200900586A1
EA200900586A1 EA200900586A EA200900586A EA200900586A1 EA 200900586 A1 EA200900586 A1 EA 200900586A1 EA 200900586 A EA200900586 A EA 200900586A EA 200900586 A EA200900586 A EA 200900586A EA 200900586 A1 EA200900586 A1 EA 200900586A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vasomotor symptoms
estrogen receptors
treating vasomotor
symptoms
selective modules
Prior art date
Application number
EA200900586A
Other languages
English (en)
Other versions
EA016613B1 (ru
Inventor
Роберт Дин Дэлли
Джеффри Алан Додж
Скотт Алан Фрэнк
Рональд Джей Хинклин
Тимоти Алан Шеферд
Оуэн Брендан Уоллас
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200900586A1 publication Critical patent/EA200900586A1/ru
Publication of EA016613B1 publication Critical patent/EA016613B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Данное изобретение относится к селективному модулятору рецепторов эстрогена формулы Iили его фармацевтической соли с кислотой, полезных для лечения вазомоторных симптомов.
EA200900586A 2004-01-22 2005-01-18 Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов EA016613B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53834204P 2004-01-22 2004-01-22
US53844204P 2004-01-22 2004-01-22

Publications (2)

Publication Number Publication Date
EA200900586A1 true EA200900586A1 (ru) 2009-08-28
EA016613B1 EA016613B1 (ru) 2012-06-29

Family

ID=34830456

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200601353A EA012262B1 (ru) 2004-01-22 2005-01-18 Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
EA200900586A EA016613B1 (ru) 2004-01-22 2005-01-18 Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200601353A EA012262B1 (ru) 2004-01-22 2005-01-18 Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов

Country Status (20)

Country Link
US (2) US20090023917A1 (ru)
EP (1) EP1709021B1 (ru)
JP (1) JP4909086B2 (ru)
KR (2) KR100849559B1 (ru)
CN (1) CN102250042A (ru)
AT (1) ATE476428T1 (ru)
AU (1) AU2005207821B2 (ru)
BR (1) BRPI0506721A (ru)
CA (1) CA2551956C (ru)
CR (1) CR8517A (ru)
DE (1) DE602005022673D1 (ru)
EA (2) EA012262B1 (ru)
EC (1) ECSP066711A (ru)
ES (1) ES2347973T3 (ru)
IL (1) IL176738A0 (ru)
MA (1) MA28436B1 (ru)
NO (1) NO20063760L (ru)
SG (1) SG149867A1 (ru)
UA (1) UA85862C2 (ru)
WO (1) WO2005073204A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
AU2009296974B2 (en) * 2008-09-29 2013-06-27 Eli Lilly And Company Selective estrogen repector modulator for the treatment of osteoarthritis
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR102557321B1 (ko) 2017-01-05 2023-07-18 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
EP3817821A1 (en) 2018-07-04 2021-05-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
AU2019299952B2 (en) * 2018-07-12 2022-06-16 Eli Lilly And Company Selective estrogen receptor degraders
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TW202300492A (zh) 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11926634B2 (en) 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US6509356B1 (en) * 1997-08-07 2003-01-21 Eli Lilly And Company 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity
AU2003253129B2 (en) * 2002-07-22 2008-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group

Also Published As

Publication number Publication date
JP4909086B2 (ja) 2012-04-04
ES2347973T3 (es) 2010-11-26
KR101008804B1 (ko) 2011-01-14
AU2005207821B2 (en) 2011-02-10
ATE476428T1 (de) 2010-08-15
EA200601353A1 (ru) 2007-02-27
KR20080016755A (ko) 2008-02-21
US20110281847A1 (en) 2011-11-17
ECSP066711A (es) 2006-10-31
EA016613B1 (ru) 2012-06-29
EP1709021A1 (en) 2006-10-11
KR100849559B1 (ko) 2008-07-31
EA012262B1 (ru) 2009-08-28
UA85862C2 (ru) 2009-03-10
MA28436B1 (fr) 2007-02-01
AU2005207821A1 (en) 2005-08-11
JP2007519721A (ja) 2007-07-19
BRPI0506721A (pt) 2007-05-02
SG149867A1 (en) 2009-02-27
CR8517A (es) 2006-12-01
CN102250042A (zh) 2011-11-23
US20090023917A1 (en) 2009-01-22
US8217032B2 (en) 2012-07-10
EP1709021B1 (en) 2010-08-04
CA2551956C (en) 2013-05-07
WO2005073204A1 (en) 2005-08-11
KR20060129277A (ko) 2006-12-15
CA2551956A1 (en) 2005-08-11
NO20063760L (no) 2006-10-16
IL176738A0 (en) 2006-10-31
DE602005022673D1 (de) 2010-09-16

Similar Documents

Publication Publication Date Title
EA200900586A1 (ru) Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA200870197A1 (ru) Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms)
ATE469895T1 (de) Cgrp-rezeptorantagonisten
BR0312675A (pt) Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE498615T1 (de) Triazolylphenylbenzensulfonamide
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
UA106200C2 (ru) Замещенные производные оксиндола и их применение для лечения заболеваний, зависимых от вазопресина
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
FR2927912B1 (fr) Nouveau materiau hybride organique-inorganique im-19 et son procede de preparation
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren
NO20081739L (no) Carbazole derivatives as functional 5-HT6 ligands
DE602007009286D1 (de) Isoindolderivate als ep4-rezeptoragonisten
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble
EA200970189A1 (ru) Пирролидинонанилины как модуляторы прогестероновых рецепторов
UY30237A1 (es) Inhibidores de la adenilato ciclasa soluble
UY30236A1 (es) Inhibidores de la adenilato ciclasa soluble
EA201170509A1 (ru) Селективный модулятор рецепторов эстрогена

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU